The expression level and clinical application value of serum CNPY2 in gastric cancer

CHEN Lanlan; JU Ying; LIU Duanrui; LIU Yiqing; LIU Yun; ZHANG Peili; PENG Meiyu

doi:10.3969/j.issn.1674-3806.2025.02.07

Abstract：Objective To analyze the expression level and clinical application value of serum canopy fibroblast growth factor signaling regulator 2(CNPY2)in gastric cancer.Methods The clinical data of 65 gastric cancer patients hospitalized in the Department of Gastrointestinal Surgery of Shandong Provincial Hospital Affiliated to Shandong First Medical University from December 2023 to September 2024 were collected.Among the patients,there were 39 cases of early gastric cancer(TNM stage Ⅰ)and 26 cases of progressive gastric cancer(6 cases of TNM stage Ⅱ,17 cases of TNM stage Ⅲ and 3 cases of TNM stage Ⅳ).Other 43 cases of patients with benign gastric diseases in Shandong Provincial Hospital Affiliated to Shandong First Medical University were selected as the benign group during the same period,and 52 cases of healthy individuals undergoing physical examination were selected as the control group.The levels of serum CNPY2,carcinoembryonic antigen(CEA)and carbohydrate antigen 199(CA199)were detected.The diagnostic efficacy of CNPY2,CEA,and CA199 for gastric cancer and early gastric cancer was analyzed by using receiver operating characteristic(ROC)curve.Results The median concentration of CNPY2 in the gastric cancer group(0.26 ng/miL)was higher than that in the benign group(0.21 ng/mL)and the control group(0.21 ng/mL),and the median concentration of CEA in the gastric cancer group(2.21 ng/mL)was higher than that in the benign group(1.28 ng/mL)and the control group(1.32 ng/mL),and the median concentration of CA199 in the gastric cancer group(13.70 IU/mL)was higher than that in the control group(9.26 IU/mL),and the differences were statistically significant(P＜0.05).The median concentrations of CNPY2(0.27 ng/mL)and CA199(16.95 IU/mL)in gastric cancer patients with TNM stage Ⅱ to stageⅣ(22 cases)were higher than the median concentrations of CNPY2(0.24 ng/mL)and CA199(11.05 IU/mL)in gastric cancer patients with TNM stage Ⅰ(36 cases),and the patients with poorly differentiated gastric cancer(34 cases)had a higher median concentration of CNPY2(0.27 ng/mL)than the patients with moderately to highly differentiated gastric cancer(24 cases)(0.25 ng/mL),and the median concentration of CEA(3.44 ng/mL)in the gastric cancer patients with human epidermal growth factor receptor 2(HER2)negative(18 cases)was higher than the median concentration of CEA(1.88 ng/mL)in the gastric cancer patients with HER2 positive(40 cases),and the differences were statistically significant(P＜0.05).The results of ROC curve analysis showed that using the combination of CNPY2,CEA and CA199 in diagnosis of gastric cancer[AUC(95％CI)=0.885(0.823-0.947)]and early gastric cancer[AUC(95％CI)=0.857(0.780-0.933)]had higher efficacy than using CNPY2,CEA and CA199 alone(P＜0.05).Conclusion Serum CNPY2 levels are significantly elevated in patients with gastric cancer,and the combined detection of serum CNPY2,CEA and CA199 can improve the diagnostic efficacy of gastric cancer and early gastric cancer.